$40m financing to expand AI-powered platform for clinical trials: Saama

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/lovelyday1)
(Image: Getty/lovelyday1)

Related tags: Artificial intelligence, Saama Technologies, Clinical trial

The clinical data analytics platform firm has raised $75m since 2015 and will continue to enhance both the platform and applications with new capabilities, says CEO.

Saama Technologies today announced that it has closed a $40m financing with Perceptive Advisors, a NY-based firm that focuses on supporting the life sciences industry.

Saama CEO Suresh Katta said the new funding will be used to further invest in and expand the company’s Life Science Analytics Cloud (LSAC).

The platform is powered by artificial intelligence (AI) to support clinical trial design and conduct across various development stages, according to the company.

The new financing – bringing the total Saama has raised since 2015 to $75m – also will help strengthen the company’s commercial team and build its “ecosystem of pharma partners, academia, data providers, and CROs to maximize LSAC utilization and build a suite of collective innovations,”​ Katta told us.

“Saama will continue to enhance both the platform and applications with new capabilities,” ​he added, noting recently examples including three new machine learning-based capabilities that extend the existing functionality of LSAC.

The new virtual assistant, operational and financial risk mitigation, and drug efficacy and patient safety analytics capabilities were released​ during the 10th Annual Summit for Clinical Ops Executives (SCOPE) in Orlando, FL.

Katta said, “Saama is applying Moore's Law to pharma to bring about transformative impact in life sciences by bending the cost and time curve down by applying ruthless amounts of technology to the entire ecosystem of vendors in the drug development process.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars